Endocrine Disorders: Evaluation and Management
Summary
- Exenatide and liraglutide are subcutaneously administered analogues of the gut hormone GLP-1
- Major adverse effect of exenatide and liraglutide is gastrointestinal upset
- Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid cancer or in patients with multiple endocrine neoplasia syndrome type 2
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Diabetes, Endocrine Disorders